EndoPredict (EPclin), a breast cancer prognostic test, analyzes RNA expression of 8 target genes (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP and STC2 ), 3 normalization genes (CALM2, OAZ1 and RPL37A), and 1 control gene (HBB), creating a 12-gene molecular score, which is then combined with clinical features of the tumor (tumor size and nodal status) to predict the 10-year distant recurrence (DR) rate. It can be utilized for evaluating risk of distant recurrence in newly diagnosed patients with early-stage, estrogen-receptor-positive, HER2-negative breast cancer. The test gives a score, known as an EPclin Risk score, that is reported as either ‘low’ or ‘high’ risk.
Estrogen Receptor Positive Breast Cancer, HER2 Negative Breast Cancer
AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding), BIRC5 (Baculoviral IAP repeat containing 5), CALM2 (Calmodulin 2), IL6ST (Interleukin 6 Signal Transducer), MGP (Matrix Gla Protein), OAZ1 (Ornithine Decarboxylase Antizyme 1)
See More ...
Confirmatory trial(s)